Chardan Capital Maintains Buy on 4D Molecular, Raises PT to $25

Chardan Capital Maintains Buy on 4D Molecular, Raises PT to $25

Chardan Capital, a leading research firm, has maintained its "buy" rating on 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT), while raising its price target to $25.00, according to a recent report dated July 3rd, 2025 [1]. The firm's positive outlook on the company's prospects is driven by the strong clinical trial results and the potential of its 4D-150 treatment for diabetic macular edema (DME).

The SPECTRA clinical trial, which evaluated 4D-150 in patients with DME, demonstrated significant clinical activity and durability over a 60-week period. The treatment showed sustained gains in visual acuity and anatomic control, with a clinically meaningful reduction in treatment burden compared to the standard of care, aflibercept 2mg Q8W [2][3]. These results have significantly boosted investor confidence in 4D Molecular Therapeutics' therapeutic potential.

Chardan Capital's positive assessment of 4D Molecular Therapeutics is supported by the company's strong pipeline of genetic medicine product candidates and its strategic focus on ophthalmology, cardiology, and pulmonology. The firm believes that the company's therapeutic vector evolution platform holds great promise for transforming treatment paradigms and providing unprecedented benefits to patients.

Despite the positive outlook, Chardan Capital acknowledges the challenges that 4D Molecular Therapeutics faces, including the competitive landscape and regulatory hurdles. However, the firm remains optimistic about the company's ability to navigate these challenges and achieve long-term success.

Reference List:
[1] https://www.marketbeat.com/instant-alerts/filing-decheng-capital-llc-sells-64485-shares-of-4d-molecular-therapeutics-inc-nasdaqfdmt-2025-07-30/
[2] https://www.ainvest.com/news/4d-molecular-therapeutics-shares-surge-50-89-positive-clinical-trial-results-2508/
[3] https://www.biospace.com/press-releases/4dmt-presents-positive-60-week-results-from-4d-150-spectra-clinical-trial-in-dme-and-regulatory-update